Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-07-17

FDA Approved: AMOXAPINE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

The FDA approved a supplemental application for amoxapine from Chartwell RX, LLC, updating the labeling for this generic antidepressant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amoxapine (Amoxapine)

Snippet

SUPPL AP for AMOXAPINE (AMOXAPINE)